Related Experiment Videos
[Hypertrophic cardiomyopathy. Genetic basis and clinical implications]
1Servicio de Cardiología (ICMCV), Hospital Clínic (IDIBAPS), Universidad de Barcelona, Barcelona, Spain. navarro@medicina.ub.es
Revista Espanola De Cardiologia
|October 30, 2004
Summary
Advances in molecular biology have identified over 150 mutations causing hypertrophic cardiomyopathy. This review details the functional effects of specific beta-myosin mutations, linking them to disease pathogenesis and potential therapies.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Genetics
Context:
- Hypertrophic cardiomyopathy (HCM) etiology has been significantly clarified by molecular biology advances.
- Over 150 causal mutations in 9 genes encoding contractile proteins are identified, yet pathogenetic mechanisms remain largely unknown.
Purpose:
- To review the current understanding of functional effects of specific HCM-associated mutations.
- To highlight the roles of two lethal beta-myosin mutations (Arg403Gln and Arg723Gly) in HCM pathogenesis.
- To emphasize the potential of these mutations in diagnostic and therapeutic strategies.
Summary:
- This review discusses the functional consequences of identified mutations in hypertrophic cardiomyopathy (HCM).
- It focuses on two severe beta-myosin mutations, Arg403Gln and Arg723Gly (Barcelona mutation), and their contribution to HCM.
- The discussion covers their roles in the development of hypertrophy, sudden cardiac death, and ischemia.
Impact:
- Elucidates the molecular basis of hypertrophic cardiomyopathy, aiding disease understanding.
- Highlights the significance of specific mutations in disease progression and clinical outcomes.
- Emphasizes the potential for targeted diagnostics and therapies based on identified genetic factors.